Multimodal radiopathomics for predicting immunotherapy response and prognosis in advanced non-small cell lung cancer
Year: 2026
Type: article
Study design: Observational Study
Abstract: Objectives To develop and validate an integrative radiopathomics framework combining pretreatment multiphase contrast-enhanced computed tomography (CT) radiomics and hematoxylin-and-eosin (H&E)-stained whole-slide image (WSI)-derived pathomics for assessment of immunotherapy benefit and overall survival (OS) risk stratification in advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Methods This multicenter retrospective study included 344 patients with advanced NSCLC treated with ICI-based therapy between June 2019 and June 2024. Pretreatment non-contrast, arterial-phase and venous-phase chest CT images and H&E-stained WSIs were analyzed. Radiomics, pathomics and integrated radiopathomics models were developed in the training cohort using feature selection and support vector machine to distinguish durable clinical benefit (DCB) from non-durable clinical benefit (NDB) and were evaluated in one internal and two external validation cohorts. The final radiopathomics score (RPS) was further assessed for OS stratification and incorporated with clinically relevant covariates into an interpretable survival nomogram. Results Among the 344 patients included (mean age 66.5 ± 8.5 years; 309 men), the radiopathomics model achieved an area under the receiver operating characteristic curve (AUC) of 0.972 in the training cohort, 0.882 in the internal validation cohort, and 0.908 and 0.898 in the two external validation cohorts, respectively. RPS stratified OS risk in the pooled cohort (hazard ratio 4.65, 95% confidence interval 3.41–6.34; P < 0.001) and provided additional prognostic separation within programmed death-ligand 1 (PD-L1) expression strata. A nomogram combining RPS, Eastern Cooperative Oncology Group performance status, liver metastasis and PD-L1 expression achieved concordance indices of 0.765–0.899 across validation cohorts. Conclusions The radiopathomics model integrating pretreatment multiphase contrast-enhanced CT radiomics with pathomics derived from H&E-stained WSIs consistently distinguished DCB from NDB in patients with advanced NSCLC treated with ICIs. The resulting RPS enabled OS risk stratification and provided additional prognostic separation within PD-L1 expression strata. Together, these findings offer preliminary insight into immunotherapy response and may inform individualized treatment planning.
Source: Frontiers in Immunology
Authors: Bojun Liu(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft), Junru Peng(Formal analysis, Investigation, Methodology, Supervision, Validation, Writing – original draft), Mengyu Xu(Data curation, Formal analysis, Investigation, Software, Validation, Visualization, Writing – original draft), Weibo Mao(Formal analysis, Investigation, Supervision, Validation, Visualization, Writing – review & editing), Weiming Xu(Investigation, Software, Supervision, Validation, Writing – review & editing), Jinying Wu(Formal analysis, Investigation, Software, Supervision, Validation, Writing – review & editing), Lingling Zhou(Formal analysis, Methodology, Software, Supervision, Validation, Writing – review & editing), Ye Feng(Formal analysis, Software, Supervision, Validation, Writing – review & editing), Xiaojie Zhang(Formal analysis, Investigation, Methodology, Writing – review & editing), Haokai Hua(Formal analysis, Methodology, Software, Writing – original draft), Yinuo Xu(Writing – original draft), Wenjie Wang(Writing – original draft), Linqiang Lai(Writing – review & editing), Hai Yang(Conceptualization, Supervision, Validation, Writing – review & editing), Jianfei Tu(Conceptualization, Supervision, Validation, Writing – original draft, Writing – review & editing)
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Keywords: non-small cell lung cancer, immune checkpoint inhibitors, immunotherapy response prediction, radiomics, pathomics, H&E whole-slide images, PD-L1 expression, durable clinical benefit, survival nomogram, prognostic factors, liver metastasis, ECOG performance status, advanced non-small cell lung cancer
Open Access status: gold
Estimated APC paid: $3,801
Funder: Zhejiang Medical Association
Award: G4736855
OpenAlex ID: W7235997270
